BACKGROUND: There is considerable variability in the amount of response to BTX-A
treatment between and within patients with cerebral palsy (CP). AIMS: The purpose of this …

Aim To assess the efficacy and safety of repeat abobotulinumtoxinA injections in reducing
upper limb spasticity in children with cerebral palsy (CP). Method This was a double‐blind …

Effective use of the upper limb can impact on educational outcomes, participation in
activities of daily living and vocational options for many children with cerebral palsy (CP) …

Botulinum toxin type A in the treatment of lower limb spasticity in cerebral palsy. - Abstract -
Europe PMC Sign in | Create an account https://orcid.org Europe PMC Menu About Tools …

Seven children between 2 and 15 years of age with cerebral palsy and upper extremity
dystonia were enrolled in an open-label, dose-escalation pilot clinical trial of botulinum toxin …

Purpose: The purpose of this study was to document impairment, disability, and parent
satisfaction outcomes for children with cerebral palsy who received botulinum toxin A (BtA) …

Botulinum toxin A (BTX-A) is widely used in the management of muscle spasticity in children.
However, at present the dose of BTX-A for a given patient is selected empirically. The aim of …

Evidence is increasing to suggest that botulinum toxin type A (BTX‐A) plays a role in the
management of upper extremity spasticity in the paediatric population. However, little …

This paper provides a review of the research literature that reports on the effectiveness of
botulinum toxin-A (BtA) to reduce tone and improve functional use of the upper limbs of …

Aim To assess treatment effects of botulinum toxin type A (BoNT‐A) on walking of children
with leg spasticity due to cerebral palsy (CP) compared with usual care. Method We …